Sai Life Sciences Ltd (SAILIFE) is currently trading at 1,559.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sai Life Sciences is an innovator-focused CRDMO that provides end-to-end services across drug discovery, development and commercial manufacturing for small molecules and emerging modalities, operating discovery centers in Hyderabad, Boston and Manchester and manufacturing blocks in Bidar and Hyderabad. Q1 FY27 revenue was INR553 crores, up 12% year-on-year, with the CDMO business contributing roughly 60% of revenues and CRO growing faster at about 26% year-on-year, indicating accelerating demand in services tied to earlier-stage discovery and development. Management is executing a shift from a small-molecule CRDMO to a multi-modality, technology-led integrated partner; initiatives include peptide labs, XDC Center of Excellence for conjugation and oligonucleotides, continuous flow chemistry scale-up and a formulation capability targeted for early clinical supplies. The company reiterated medium-term revenue guidance of 15%–20% and EBITDA margin targets of 28%–30%, while committing to sizeable capital deployment to expand production capacity, peptide manufacturing and clinical formulation abilities, underpinned by growing FTE engagements with large pharma. Sai Life Sciences has strengthened ESG credentials, achieving EcoVadis Platinum in 2026 (top 1% globally), while building talent programs (Sai Academy) and campus hiring initiatives to support more complex scientific and operational delivery across modalities.

Over the past 52 weeks, Sai Life Sciences Ltd has traded between a low of ₹786.15 and a high of ₹1,697.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sai Life Sciences Ltd has a market capitalization of approximately 31,763.61. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sai Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 87.81 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 31,763.61 Cr, Sai Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sai Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sai Life Sciences Ltd is 87.81. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board meeting to consider and approve Q1 FY27 unaudited results is scheduled for August 6, 2026.

The Board of Directors is scheduled to meet on August 6, 2026, to consider and approve the unaudited results for the quarter ended June 30, 2026.

Pharma shares gained after the Pentagon named WuXi AppTec on a list of firms associated with the Chinese military, which investors viewed as supportive for India-based outsourcing alternatives.

It reported revenue growth of 36%, EBITDA growth of 43%, and net profit growth of 100% for Q2 and the half year ended September 2025.